Navigation Links
Telik Announces Presentation at ASCO Annual Meeting
Date:5/21/2009

PALO ALTO, Calif., May 21 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced today that the results from the randomized clinical study of canfosfamide (TELCYTA(R), TLK286) in combination with pegylated liposomal doxorubicin (PLD) vs. PLD will be presented at the 45th annual meeting of the American Society of Clinical Oncology (ASCO) which will be held from May 29 to June 2 in Orlando, FL.

Details of the presentation are as follows:

           -- Abstract #5552 - General Poster Session, Gynecologic Cancer;
              Sunday, May 31, 2009, 2:00-6:00pm EDT; Level 2, West Hall C

              Title:  "Randomized phase III study of canfosfamide (C, TLK286)
              plus pegylated liposomal doxorubicin (PLD) versus PLD as
              second-line therapy in platinum (P) refractory or resistant
              ovarian cancer (OC)."

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates.

TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
2. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
3. Telik Announces Telintra Presentation at American Society of Hematology Annual Meeting
4. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
5. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
6. Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia
7. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
8. TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
9. Feldenkrais(R) Movement Institute Announces Simple Non-Surgical Solutions for Jaw and Facial Pain (TMJ)
10. DSM Announces Yield Boosts of 5-10 Fold With XD(R) Technology for Mammalian Manufacturing Platforms
11. TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... , October 31, 2014 ... clinical-stage pharmaceutical company focused on the development of ... will host a conference call to discuss the ... of ORMD-0801, the company,s proprietary oral insulin capsules, ... 3, 2014 at 10:00 a.m. Eastern time. ...
(Date:10/31/2014)... October 31, 2014 Today, Analysts ... CELG ), Bristol-Myers Squibb Co. (NYSE: ... UNH ), Sanofi SA (NYSE: SNY ) ... these notes ahead of publication. To reserve complementary membership, ... ,-- ,Celgene Corporation Research Reports ,On October 23, 2014, ...
(Date:10/31/2014)... CHICAGO , Oct. 31, 2014  Zacks.com announces the list ... Equity Research analysts discuss the latest news and events impacting stocks ... Amgen (Nasdaq: AMGN - Free Report ), Celgene ... (Nasdaq: BIIB - Free Report ), Market Vectors ... and SPDR S&P Biotech ETF (AMEX: XBI - ...
Breaking Medicine Technology:Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 2The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 4The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 5The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 6The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 7
... and Effective in Patients ... Open-Heart Surgery, WASHINGTON, Sept. 1 Data announced ... very complex coronary,artery disease can safely choose to be ... says The Society for,Cardiovascular Angiography and Interventions (SCAI). The ...
... recent,concern that suicide may be a complication of ... Administration (FDA) approved oral,drug that has been prescribed ... of,asthma and seasonal allergy symptoms. An independent study ... evidence of depression or suicide,linked to montelukast., ...
Cached Medicine Technology:SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease 2SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease 3American Lung Association Study Finds No Evidence of Depression or Suicide Linked to Asthma and Allergy Drug Montelukast 2American Lung Association Study Finds No Evidence of Depression or Suicide Linked to Asthma and Allergy Drug Montelukast 3
(Date:10/31/2014)... (PRWEB) October 31, 2014 Daily Gossip writes ... is actually described as the fastest fat loss program ever ... less than a month. , There is no wonder after ... eBook of all time. The new nutrition and workout fat ... and fitness expert. , According to the author of ...
(Date:10/31/2014)... Activz Whole-Food Nutrition is ... line offering natural silver healing support† in liquid supplements, ... silver has been used to support natural healing, and ... the most advanced version available. This latest formula, backed ... that supports the existing healing mechanisms in the human ...
(Date:10/31/2014)... terms of duration of treatment and cost, patients ... accelerated partial breast irradiation (APBI) with proton therapy ... research from The University of Texas MD Anderson ... cost analysis study based on typical patient characteristics, ... charges for eight different types of partial and ...
(Date:10/31/2014)... The Suspension Revolution review published by Daily Gossip ... Dan Long, a suspension training specialist. , Long ... life coach. The author of this program claims that ... impossible , The Suspension Revolution review reveals that this ... efficiency when it comes to burning fat, building muscles, ...
(Date:10/31/2014)... York, NY (PRWEB) October 31, 2014 ... one of the most remarkable gifts of life — ... platform for matching extraordinary surrogate mothers and donors with ... about individuals in unforeseen circumstances. , It’s a collective ... donors, surrogacy agencies, surrogacy lawyers, and fertility clinics that ...
Breaking Medicine News(10 mins):Health News:Xtreme Fat Loss Diet Review Reveals How to Transform Your Body in 25 Days 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 4Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Suspension Revolution Review Reveals Dan Long's New Suspension Workout Plan 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 3
... WASHINGTON, May 12 Speaker Nancy Pelosi released ... the Social Security and Medicare Trustees, which was released ... of the Social Security and Medicare trust funds. ... left behind a record of recession, deficits and debt, ...
... In a meeting today with President Obama and ... Inc. (REI) drew praise for their innovative employee health ... Association (RILA).Following the meeting, President Obama referred to the ... and Safeway President and CEO Steven Burd, as "some ...
... to hear world voices, especially voices from Africa, about ... , - Dr. Paul Zeitz, GAA executive directorWASHINGTON, May ... than 12,000 health advocates and organizations around the world, ... Zeitz called for a worldwide response to fix ...
... PARS) today reported results for the first quarter ended March ... million, or $0.14 per share, for the first quarter 2009 ... per share, in the first quarter 2008. Cash and short-term ... in net loss for the first quarter 2009 vs. first ...
... Nektar Therapeutics (Nasdaq: NKTR ) is scheduled ... Care Conference in Boston at the Boston InterContinental Hotel on ... will be accessible via a Webcast through a link posted ... website: http://www.nektar.com . This ...
... BurrellesLuce is sponsoring a multifaceted look at "Advanced PR Strategies," one of ... Summit, to take place Sunday, May 17, through Tuesday, May 19, in ... ... BurrellesLuce is sponsoring a multifaceted look at "Advanced PR Strategies," ...
Cached Medicine News:Health News:President Obama Praises Retailers as Part of the Health Care Solution 2Health News:GAA Calls For a Worldwide Response to President Obama's Global Health Budget Shortfalls 2Health News:Pharmos Corporation Reports 2009 First Quarter Results 2Health News:Pharmos Corporation Reports 2009 First Quarter Results 3Health News:Pharmos Corporation Reports 2009 First Quarter Results 4Health News:Pharmos Corporation Reports 2009 First Quarter Results 5Health News:BurrellesLuce Sponsoring Track on 'Advanced PR Strategies' At Annual Industry Summit to Be Held May 17-19 in New York 2Health News:BurrellesLuce Sponsoring Track on 'Advanced PR Strategies' At Annual Industry Summit to Be Held May 17-19 in New York 3
Magniclear is the first presbyopic lens to combine the clear distance optics of a spherical lens, the intermediate visual performance of a multifocal and the predictably crisp, near power of a bifoca...
... is a simultaneous vision lens ... Through a series of front ... LifeStyle Gp delivers up to ... its multi-aspheric center-distance design works ...
Gendron ophthalmic eye surgery stretcher....
... surgical stretcher. M-701 Stretcher has a ... to 32 in., measured with a ... a high range, 28 in. to ... pad can be supplied optionally. Vinyl ...
Medicine Products: